Levothyroxine Sample size and study design [Power / Sample Size]

posted by bebac_fan – US, 2018-04-12 22:49 (1335 d 12:40 ago) – Posting: # 18674
Views: 3,067

Dear Prasad,

OGD product specific guidance is for 2x2x4, following NTID rules (laid out in Warfarin guidance). Yes, this is a recent change, most levo generic drugs on market right now were approved with a CO study. Current OND guidance (for NDA) is 2x2x2 crossover.

Variability would be much smaller without baseline correction. For either test, baseline correction must be applied, which is subtracting the average of 3 predose measurements from all further PK samples.

Regarding the studies you found with a sample size of 50-72, that may be required if they were powering the study for the NTID test. OR, the large sample size may be used to pass a drug with a small (e.g. GMR of 1.05) bias. AFAIK the FDA doesn't get too upset over conservative sample sizes unless they are outrageous.

Hope that helps,
BF

Complete thread:

Activity
 Admin contact
21,788 posts in 4,557 threads, 1,548 registered users;
online 14 (0 registered, 14 guests [including 3 identified bots]).
Forum time: Wednesday 10:30 CET (Europe/Vienna)

There is no adequate defense, except stupidity,
against the impact of a new idea.    Percy Williams Bridgman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5